R&D News | pharmaphorum

News

AZ's bid for Fasenra approval in COPD falls short

AstraZeneca has abandoned Fasenra development in COPD, but there is better news for the company with a new version of lupus drug Saphnelo.

News

Study finds Novo's Wegovy turns down 'food noise'

Novo Nordisk has said a real-world survey of Wegovy shows it can reduce 'food noise', persistent, intrusive, or repetitive thoughts about eating.

News

Novartis agrees $5.7bn degrader deal with Monte Rosa

Novartis has signed its second multibillion-dollar licensing deal with molecular glue degrader specialist Monte Rosa in less than a year.

News

High dose of Wegovy drives weight loss to 19%

A triple dose of Novo Nordisk's GLP-1 agonist Wegovy has shown improved activity on weight loss in an obesity trial versus the current formulation.

News

AZ halts UK investment, and Lilly, Sanofi follow suit

After MSD's bombshell retreat from a big UK investment plan, AstraZeneca, Lilly, and Sanofi are also pressing pause on new projects.

News

Reaction to MSD's UK exit as government tries to renew talks

The UK government is reported to be trying to restart talks over drug pricing and rebates after MSD's shock decision to scrap a £1bn investment spend.

AZ's bid for Fasenra approval in COPD falls short

Study finds Novo's Wegovy turns down 'food noise'

Novartis agrees $5.7bn degrader deal with Monte Rosa

High dose of Wegovy drives weight loss to 19%

AZ halts UK investment, and Lilly, Sanofi follow suit

Reaction to MSD's UK exit as government tries to renew talks

CDC panel votes to scrap hepatitis B birth dose advice

How to meet your physicians where they are online

News

Editor's Picks